surmount-1 trial tirzepatide weight loss non-diabetic after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 𝗠𝗼𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮𝘀𝘀𝘂𝗺𝗲 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁

The medication is administered as a once-weekly subcutaneous injection, starting with a low dose (0.25 mg) that is gradually increased over 16 weeks to the maintenance dose of 2.4 mg

They're optimized for volume

STEP 4 (maintenance, JAMA 2021)

[1]) to deliver enzymes/proteins into cells

they are very warm, welcoming and so easy to talk to about anything you want to know or have concerns about

When to Consider Switching Medications or Adding Genetic Testing The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R, GIPR, FTO, and MC4R variants that relate to GLP-1 and related signaling pathways